The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Predicting protein structures with a multiplayer online game
Cooper, S., Khatib, F., Treuille, A., Barbero, J., Lee, J., Beenen, M., Leaver-Fay, A., Baker, D., Popović, Z., & players, F. (2010) · Nature · doi:10.1038/nature09304 · Cited by 1,368
Self-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011) · Science · doi:10.1126/science.1213256 · Cited by 694
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Advances in protein structure prediction and design
Kuhlman, B., & Bradley, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0163-x · Cited by 806
Self-citationAntibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Sockolosky, J. T., Trotta, E., Parisi, G., Picton, L., Su, L. L., Le, A. C., Chhabra, A., Silveria, S. L., George, B. M., King, I. C., et al. (2018) · Science · doi:10.1126/science.aar3246 · Cited by 382
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Dillon, M., Yin, Y., Zhou, J., McCarty, L., Ellerman, D., Slaga, D., Junttila, T. T., Han, G., Sandoval, W., Ovacik, M. A., et al. (2017) · mAbs · doi:10.1080/19420862.2016.1267089 · Cited by 75
“This reflects the potential for up to nine mispaired IgG species with single-cell BsIgG, compared with only two mispaired IgG for dual-cell BsIgG.”
BackgroundMethodResultInfluentialAntibody H3 structure prediction
Marks, C., & Deane, C. M. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2017.01.010 · Cited by 56
Sphinx: merging knowledge-based and ab initio approaches to improve protein loop prediction
Marks, C., Nowak, J., Klostermann, S., Georges, G., Dunbar, J., Shi, J., Kelm, S., & Deane, C. M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw823 · Cited by 56
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Froning, K., Maguire, J., Sereno, A., Huang, F., Chang, S., Weichert, K., Frommelt, A. J., Dong, J., Wu, X., Austin, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16231-7 · Cited by 37
Self-citationAntibody side chain conformations are position-dependent
Leem, J., Georges, G., Shi, J., & Deane, C. M. (2018) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25453 · Cited by 22
Hallucinating structure-conditioned antibody libraries for target-specific binders
Mahajan, S. P., Ruffolo, J. A., Frick, R., & Gray, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999034 · Cited by 20
“1CE1[38] Alemtuzumab 21 6BFT[39] Bevacizumab 74 6NOV[40] Ixekizumab 24 4LLU[41] Pertuzumab 85 5WUV[42] Certolizumab 100 5B8C[43] Pembrolizumab 34 6TCS[44] Omalizumab 36 5XXY[45] Atezolizumab 93 1N8Z[37] Trastuzumab 43”
Metadata
- Authors
- Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., Hansen-Estruch, C., Chamberlain, A. K., Truhlar, S. M., Conner, E. M., Atwell, S., Kuhlman, B., & Demarest, S. J.
- Venue
- Nature Biotechnology
- Published
- 2014-01-26
- Volume
- 32
- Issue
- 2
- Pages
- 191-198
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2053872195
- Cited by
- 234
- References
- 5
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.